Additionally, the 36-month beta value for CRNX is 0.61. There are mixed opinions on the stock, with 8 analysts rating it as a “buy,” 5 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for CRNX is 85.22M and currently, short sellers hold a 8.15% ratio of that float. The average trading volume of CRNX on November 15, 2024 was 678.54K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CRNX) stock’s latest price update
The stock price of Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) has surged by 1.26 when compared to previous closing price of 58.92, but the company has seen a -0.25% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-14 that Novel Nonpeptide Drug Conjugate Platform to be Debuted, Featuring Preclinical Profile of Lead Candidate CRN09682 Targeting SST2-Expressing Tumors, which is on Track for IND Submission Early 2025
CRNX’s Market Performance
Crinetics Pharmaceuticals Inc (CRNX) has seen a -0.25% fall in stock performance for the week, with a 1.36% gain in the past month and a 15.58% surge in the past quarter. The volatility ratio for the week is 4.54%, and the volatility levels for the past 30 days are at 3.58% for CRNX. The simple moving average for the past 20 days is 2.33% for CRNX’s stock, with a 23.09% simple moving average for the past 200 days.
Analysts’ Opinion of CRNX
Many brokerage firms have already submitted their reports for CRNX stocks, with Citigroup repeating the rating for CRNX by listing it as a “Buy.” The predicted price for CRNX in the upcoming period, according to Citigroup is $68 based on the research report published on March 06, 2024 of the current year 2024.
Morgan Stanley, on the other hand, stated in their research note that they expect to see CRNX reach a price target of $50. The rating they have provided for CRNX stocks is “Overweight” according to the report published on January 16th, 2024.
Jefferies gave a rating of “Hold” to CRNX, setting the target price at $35 in the report published on December 21st of the previous year.
CRNX Trading at 8.71% from the 50-Day Moving Average
After a stumble in the market that brought CRNX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -3.77% of loss for the given period.
Volatility was left at 3.58%, however, over the last 30 days, the volatility rate increased by 4.54%, as shares surge +1.26% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +17.03% upper at present.
During the last 5 trading sessions, CRNX fell by -0.25%, which changed the moving average for the period of 200-days by +63.54% in comparison to the 20-day moving average, which settled at $58.30. In addition, Crinetics Pharmaceuticals Inc saw 67.68% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRNX starting from Pizzuti Dana, who sale 14,375 shares at the price of $54.63 back on Oct 03 ’24. After this action, Pizzuti Dana now owns 28,507 shares of Crinetics Pharmaceuticals Inc, valued at $785,306 using the latest closing price.
DANA J PIZZUTI, the Officer of Crinetics Pharmaceuticals Inc, proposed sale 14,375 shares at $54.63 during a trade that took place back on Oct 03 ’24, which means that DANA J PIZZUTI is holding shares at $785,322 based on the most recent closing price.
Stock Fundamentals for CRNX
Current profitability levels for the company are sitting at:
- -295.87 for the present operating margin
- -0.43 for the gross margin
The net margin for Crinetics Pharmaceuticals Inc stands at -267.48. The total capital return value is set at -0.35. Equity return is now at value -40.26, with -35.20 for asset returns.
Based on Crinetics Pharmaceuticals Inc (CRNX), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -3.8.
Currently, EBITDA for the company is -221.51 million with net debt to EBITDA at 0.87. When we switch over and look at the enterprise to sales, we see a ratio of 4915.1. The liquidity ratio also appears to be rather interesting for investors as it stands at 16.38.
Conclusion
In conclusion, Crinetics Pharmaceuticals Inc (CRNX) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
